Check this box if no

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	23)													
1. Name and Address of Reporting Person Barbier Ann (Last) (First) (Middle) C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR (Street)			2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [PIRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
			DIG 055	3. Date of Earliest Transaction (Month/Day/Year) 01/25/2019						Officer (give title below) Other (specify below)				<i>i</i>)	
			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
BOSTON (Cit	N, MA 021	(State)	(Zip)			Table	1 - N	on-Deriva	tive Securities	Acquired					
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Deer Execution any (Month/I	n Date,	3. T Coo (Ins	Fransa	action 4. (A	Securities Acqu) or Disposed of (astr. 3, 4 and 5)	uired 5. A	5. Amount of Securities Beneficia Owned Following Reported Transaction(s) (Instr. 3 and 4)		Beneficially ed	Ownership of Form:	7. Nature of Indirect Beneficial Ownership Instr. 4)
									ed in this for					ne	
								form dis	ed in this for splays a curre sed of, or Bene evertible secur	ently vali	id OMB co			ne	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	stion of De Ac (A	Numberivative curities equired or	er 6 F 7e (form dis red, Dispos ptions, con	splays a curre sed of, or Bene evertible secur reisable and Date	ently vali	wned	8. Price of	9. Number of Derivative Securities Beneficially Owned Following	f 10. Ownersh Form of	
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	stion of Do	Numberivative curities equired) or sposed) sstr. 3,	er 6 F Ve (form dis	splays a curre sed of, or Bene evertible secur reisable and Date	eficially O ities) 7. Title ar Amount o Underlyir Securities	wned	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	f 10. Ownersh Form of Derivativ Security: Direct (D or Indirec	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion of Do (A) Se (A) Di (II an	Numberivative curities equired of or sposed of str. 3, d 5)	nts, oper 6	form dis	sed of, or Benevertible secur recisable and Date y/Year)	eficially O ities) 7. Title ar Amount o Underlyir Securities	wned	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	f 10. Ownersh Form of Derivativ Security: Direct (D or Indirec s) (I)	of Indirect Beneficia Ownershi (Instr. 4)

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting 6 wher reame, readless	Director	10% Owner	Officer	Other		
Barbier Ann C/O PIERIS PHARMACEUTICALS, INC. 255 STATE STREET, 9TH FLOOR BOSTON, MA 02109	X					

Signatures

/s/ Marc D. Mantell, Esq, Attorney-in-Fact	01/29/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.